Surgery to remove the prostate with hormone and drug therapy in advanced prostate cancer
Tests prostate removal surgery plus hormone and drug therapy in men with spread prostate cancer.
Plain-language title generated from the registry record
Registry title: Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
Key facts
- Where
- Nanjing, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06350825, who can take part
Where in China
- The First Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital with Nanjing Medical University
- Trial code
- NCT06350825
- Record updated
- 5 April 2024
- Original description
To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)Read full original descriptionShow less
Evaluating the Efficacy and Safety of Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer
To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)
Inclusion: Male aged ≥18 and ≤75; Histologically confirmed prostate adenocarcinoma; Evidence of metastasis confirmed by magnetic resonance imaging (MRI)/computed tomography (CT) scan, bone scan, or histology; Clinical stage M1a (distant lymph node positive), M1b (bone metastasis), or M1c (visceral organ metastasis); Prostate cancer has not received local treatment (e.g., prostate radiotherapy, cryotherapy, etc.); The surgeon believes the prostate can be removed.
Exclusion: History of prior local treatment for prostate cancer; Difficulty swallowing, chronic diarrhea, intestinal obstruction, and other factors affecting drug intake and absorption; The surgeon believes the disease is unresectable; Life expectancy less than 2 years; Active spinal cord compression; Refusal to sign the informed consent; Investigator believes the individual is not suitable for inclusion.